Entrada Therapeutics, Inc. Common Stock (NASDAQ: TRDA) last traded at $5.67, up 2.53% on the session. The quote above updates while this page is open; the figures below are drawn from Entrada Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Entrada Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker TRDA. Its market capitalisation is $220.77 million.
Valuation measures for Entrada Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $220.77M |
|---|---|
| Enterprise value | $186.96M |
| Price / sales | 47.11 |
| Price / book | 0.95 |
| Beta | 1.31 |
Trailing-twelve-month figures tagged in Entrada Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $4.69M |
|---|---|
| Net income (TTM) | -$165.78M |
| EPS (TTM) | -$3.97 |
| Operating margin | -3767.07% |
| Return on equity | -71.02% |
| Cash | $99.28M |
Range and volume for TRDA over the past 52 weeks.
| 52-week high | $16.45 |
|---|---|
| 52-week low | $5.15 |
| Volume | 209.4K |
| Average volume | 353.0K |
| Previous close | $5.53 |
Invest a chosen dollar amount in Entrada Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell TRDA.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.